Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Well, new year, new prez, new ideas on healthcare. Let's see where this goes.
Looks like with all the insurers dropping out of Obamacare exchanges, which are going down in flames, no one was making any money off of it. Surprising since govt programs are rife with inefficiencies, loopholes, and corruption. You would think that some small pink sheet stocks would come up with some scams.
Maybe. Not sure. First thing (to borrow from Shakespeare) is to gt rid of all the ambulance chasing lawyers.
i agree/ trump in control. should be good for some. insurance companies ?????
well, with Trump on the way to the nomination, we're a step closer to overturning Obamacare. Just need to keep Hillary out of the White House.
Obamacare and the market are the two things keeping me from early retirement right now. The market will fix itself long before Obamacare gets fixed.
i agree, someone got an answer/ thanx
and the disaster continues.
Opt out. Did it last year and will do it again. Filing for religious exemption this year. Government can not and will not force me to have insurance. I hate U.S. medical system. It is all about profits and selling treatment. They do not want cures. Google Dr. Bob Beck to liberate yourself from pharmaceuticals.
STOLE OVER 700 billion for medicare.
nope. Hard to explain Obamacare other than it is a disaster.
CAN ya explain dis ????? advertising for medicare ?????
obamacare added some options to medicare ?????
medicare booklet doesn't show these items.
teeth
prescriptions
apply for more benefits ????? money increase,
The sad truth is I doubt many in Congress would have read it even if it were a bill of only 100 pages or less.
I wish Congress would have paid more attention and read the Obamacre bill before passing it. http://news.yahoo.com/obamacare-condition-gone-critical-life-113000762.html
Looking back at this SCRC is now .0255 x .03. Hope you did not invest here.
I wish we would have paid a little more attention to GENE.
I looked at this before and something struck me as not being right about this company. Can't remember what that was, but did not buy.
illegal, seems SCRC was a buy at .11.I am not sure if it is a buy at .20.I need to see another profitable quarter before investing at the current price.
I took a brief look at SCRC a short while back but then immediately forgot about it. TY for bringing it to my attention again. I think the pps has a lot of potential to make a nice high rise.
illegal,If only I knew the company would be as profitable this quarter as it was last quarter.
TYSONS CORNER, VA--(Marketwired - Dec 3, 2014) - ScripsAmerica, Inc. (OTCBB: SCRC) today announced that its wholly owned subsidiary, Main Avenue Pharmacy, reported $5,257,753 in approved orders during November of 2014. This represents the third consecutive month that ScripsAmerica's specialty pharmacy generated over $5 million in sales.
CEO of ScripsAmerica, Bob Schneiderman, commented, "We are pleased that our specialty pharmacy continues to report tremendous revenues and is maintaining an annual run rate over $60 million. As ScripsAmerica closes 2014 in a very strong financial position where revenues have experienced dramatic growth, we are currently profitable and have a favorable capital structure with less than 138 million shares outstanding, we believe the company is greatly undervalued right now."
"Management is highly committed to maximizing Scrips' exposure in the investment community in order to propel the Company toward an accurate valuation which would increase shareholder value significantly," added Schneiderman.
About ScripsAmerica, Inc.
ScripsAmerica, Inc. is a supplier of prescription, OTC and nutraceutical drugs, delivering pharmaceutical products to a wide range of end users across the health care industry. End users include retail pharmacies, hospitals, long-term care facilities and government and home care agencies. For more information, visit www.ScripsAmerica.com.
Salty,
SCRC made a nice profit last quarter, if the company is profitable this quarter SCRC may be a winner,
TYSONS CORNER, VA--(Marketwired - Dec 10, 2014) - ScripsAmerica, Inc. (OTCBB: SCRC) today announced that the Company has secured a $4 million line of credit from Triumph Healthcare Finance. The line of credit will be used by ScripsAmerica to fund the expansion of its specialty pharmacy operations in the US and pay off its current high interest debt.
"We view our collaboration with ScripsAmerica not just as a loan, but as the beginning of a value-added relationship," stated Jennifer Sheasgreen, President of Triumph Healthcare Finance. "Triumph looks forward to developing a lasting bond with Jeff, Bob and the entire Scrips team as the Company continues its growth in the pharmaceutical and healthcare industries," continued Sheasgreen.
Bob Schneiderman, CEO of ScripsAmerica, added, "Given our specialty pharmacy division's tremendously successful year and ScripsAmerica's plan to sustain this growth in 2015, it is a positive and logical step to partner with a leading financial institution and gain access to additional working capital to fund our expansion efforts. Working with Jennifer and Triumph Healthcare Finance has been an enjoyable and satisfying experience and we at ScripsAmerica look forward to having a long and mutually beneficial working relationship with Triumph Healthcare Finance," commented Bob Schneiderman, Scrips CEO.
About Triumph Healthcare Finance
Triumph Healthcare Finance specializes in helping smaller middle-market healthcare companies and other service providers that would benefit from revolving lines of credit secured by insurance, government or contract accounts receivable. Funds may be used for a variety of purposes, including turnarounds, restructurings, M&A financing or general working capital. For more information, visit www.triumphhf.com. Triumph Community Bank, N.A. d/b/a Triumph Healthcare Finance.
About ScripsAmerica, Inc.
ScripsAmerica, Inc. is a supplier of prescription, OTC and nutraceutical drugs, delivering pharmaceutical products to a wide range of end users across the health care industry. End users include retail pharmacies, hospitals, long-term care facilities and government and home care agencies. For more information, visit www.ScripsAmerica.com.
Thanks. I'll take a look.
illegal, SCRC may be a stock to watch.
Hi Salty,
Too bad HASC has so many shares outstanding.
Good article. TY for posting.
ADDISON, TX--(Marketwired - Nov 13, 2014) - HASCO Medical, Inc. (PINKSHEETS: HASC), a leading provider of handicap-accessible vans, parts and service, reported results for the third quarter ended September 30, 2014.
Q3 2014 Financial and Operational Highlights
Revenues up 22% to $23.8 million over Q3 2013
Service and other revenue up 31% to $4.2 million vs. year-ago quarter
Gross profit increased 34% to $6.3 million over the same year-ago quarter
Net income increased 93% to a record $0.8 million vs. Q3 2013
Completed divestiture of Certified Medical's durable medical equipment business, now only public company operating as a pure-play vehicular mobility provider
Secured the rights to market BraunAbility® and Vantage Mobility International (VMI) wheelchair accessible vans in Miami, Florida
First Nine Months of 2014 Financial Highlights
Revenues increased 29% to a record $68.4 million
Gross profit up 34% to a record $16.6 million
Net income increased 168% to a record $1.3 million
Q3 2014 Financial Summary
Net revenues for the third quarter of 2014 totaled $23.8 million, up 22% from $19.5 million in the same year-ago quarter. Service and other revenue totaled $4.2 million, up 31% from the same year-ago quarter. The improvements were primarily due to the increase in private-pay business for van sales, as well as the contribution of Auto Mobility Sales which was acquired last September. The increase in service and other revenue is also due to the contribution of custom configuration and sale of nearly 30 taxis.
Gross profit was $6.3 million or 26.5% of total net revenues, compared to $4.7 million or 24.2% of total net revenues in the same year-ago quarter. The gross margin increase is due to an increase in service revenue which is a higher margin segment.
Net income totaled a record $802,000, as compared to net income of $417,000 in the same year-ago quarter.
First Nine Months of 2014 Financial Summary
Net revenues for the first nine months of 2014 totaled a record $68.4 million, up 29% from $53.0 million in the first nine months of 2013. Service and other revenue totaled $12.0 million, up 26% from the same year-ago period.
Gross profit was a record $16.6 million or 24.3% of total net revenues, compared to $12.3 million or 23.3% of total net revenues in the same year-ago period. The gross margin improvement is due to the greater buying power and utilization of capacity in service.
Net income totaled a record $1.3 million, as compared to net income of $0.5 million in the same year-ago period.
Management Commentary
"Our third quarter record profitability reflects the increasing success of our brands and stores across the East Coast, as well as the effective execution of our growth plan by our management team," said Hal Compton, CEO of HASCO Medical. "To support continued growth, we are expanding our footprint on the East Coast. This includes the opening of a new wheelchair accessible van dealership to service customers in the Baltimore metropolitan area, which marks our 20th location.
"With the support of major brands like BraunAbility and VMI, we plan to open another dealership in the current quarter that will support our continued organic growth. We will remain opportunistic for additional stores in the highly fragmented, large and thriving vehicular mobility market.
"We are in the process of approving store demos and marketing materials designed to provide more interactivity and up-sell opportunities, which we expect to roll out in the current quarter. In addition, we are testing new mobility products from Pride Mobility and Harmar in two of our stores, and expect to launch the roll out to all of our stores in the first quarter of 2015.
"We see our expanding customer base driving further growth in recurring, high-margin service revenue, and we remain on track for a record topline and continued growth in profitability for the year."
About HASCO Medical, Inc.
HASCO Medical is a leading provider of handicap accessible vans, parts, and service that dramatically improve the quality of living of its customers. The company operates 20 locations from Maine to Florida. The company's mobility brands include Ride-Away (www.Ride-Away.com), Mobility Freedom (www.MobilityFreedom.com) and Wheelchair Vans of America (www.wcvans.com). To learn more, go to www.hascomed.com.
Cautionary Note Regarding Forward-Looking Statements
This press release may contain forward-looking statements, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. In some cases you can identify those so-called "forward looking statements" by words such as "may," "will," "should," "expects," "plans," "targets," "believes," "anticipates," "estimates," "predicts," "potential," or "continue" or the negative of those words and other comparable words. These forward looking statements are subject to risks and uncertainties, product tests, commercialization risks, availability of financing and results of financing efforts that could cause actual results to differ materially from historical results or those anticipated. Further information regarding these and other risks is described from time to time in the Company's filings with the SEC, which are available on its website at: http://www.sec.gov. We assume no obligation to update or alter our forward-looking statements made in this release or in any periodic report filed by us under the Securities Exchange Act of 1934 or any other document, whether as a result of new information, future events or otherwise, except as otherwise required by applicable federal securities laws.
Hasco Medical, Inc. & Subsidiaries
Consolidated Balance Sheets
(unaudited)
September 30, December 31,
2014 2013
Assets
Current assets
Cash $ 610,714 $ 150,313
Accounts receivable, net of allowance for doubtful accounts of $661,250 and $686,345, respectively 8,424,671 6,182,680
Inventory, net 13,782,135 11,572,060
Deferred tax asset, short term 489,014 413,193
Current portion of note receivable 25,505 -
Prepaid expenses and other current assets 519,285 504,819
Total current assets 23,851,324 18,823,065
Property & equipment, net of accumulated depreciation of $1,774,036 and $1,164,634, respectively 2,097,319 2,141,212
Intangible assets, net of accumulated depreciation of $43,285 and $10,192, respectively 6,180,941 6,214,034
Deferred tax asset, long term 181,212 149,204
Note receivable, net of current portion 94,950 -
Other non-current assets 596,609 604,965
Total Assets $ 33,002,355 $ 27,932,480
Liabilities and Stockholders' Equity
Current liabilities
Accounts payable and accrued expenses $ 2,763,262 $ 1,849,702
Cash overdraft -- 175,572
Customer deposits and deferred revenue 298,804 388,433
Line of credit 3,140,346 2,303,143
Note payable - floor plan 13,160,906 12,174,639
Obligation under capital leases 406,392 366,658
Current portion of notes payable 392,597 376,685
Current portion note payable, related party 355,640 353,008
Other current liabilities 2,012,063 493,923
Total current liabilities 22,530,010 18,481,763
Obligation under capital leases, net of current portion 1,008,521 817,828
Notes payable, net of current portion 3,746,157 4,075,802
Notes payable to related party, net of current portion 1,699,567 1,947,214
Total liabilities 28,984,255 25,322,607
Stockholders' Equity
Preferred stock, $0.001 par value, 3,000,000 shares authorized, none issued and outstanding -- --
Common stock, $0.001 par value, 2,000,000,000 shares authorized; and 1,000,575,949 and 993,134,076 shares issued and outstanding, respectively
The Ebola news keeps getting worse.
“The Famine Early Warning Network known as FEWS NET said in an Oct. 10 report that if the number of Ebola cases reaches 200,000-250,000 by mid-January, large numbers of people in the three worst-affected countries would face moderate to extreme food shortages.”
http://news.yahoo.com/ebola-escalation-could-trigger-major-food-crisis-043927850.html
There has got to be a reason for citing those numbers….
Now, more researches are saying it can be airborne in exhaled particulates:
http://www.inquisitr.com/1541821/ebola-is-airborne-university-of-minnesota-cidrap-researchers-claim/
New on my Christmas wish list:
http://www.grainger.com/product/SUNDSTROM-SAFETY-Powered-Air-Purifying-Respirator-WP117852/_/N-bzc?redirect=Papr&s_pp=false&picUrl=//static.grainger.com/rp/s/is/image/Grainger/33W802_AS01?$smthumb$
3M is a manufacturer of PAPRs
Yes, lots of shares, but nice to see that they are profitable and reporting.
PGLA
Company Background
Progen Pharmaceuticals Limited is an Australia-based biotechnology company. The principal activities of the Company during the fiscal year ended June 30, 2012 (fiscal 2012), included discovery, research and development of potential biopharmaceutical therapeutics for the treatment of human diseases, and the provision of contract services related to the process development, manufacture and assurance of biological products. The Company operates in two segments: research and development and manufacturing. The primary activities of the research and development division were Preclinical and clinical development of PG545, and the clinical development of other drug candidates including PG11047 and the Phase 2 PI-88 melanoma program. It operates a currently Good Manufacturing Practices (cGMP), certified manufacturing facility that provides contract manufacturing services to the biotechnology industry. The Company's pipeline includes angiogenesis, cell proliferation and epigenetics series.
http://www.progen.com.au
HASC .03 lots of shares outstanding.
Q2 2014 Financial Summary
Net revenues for the second quarter of 2014 totaled a record $24.0 million, up 28% from $18.7 million in the same year-ago quarter. The improvement was primarily due to the increase in private-pay business for van sales, as well as the contribution of Auto Mobility Sales that the company acquired last September. Service and other revenue totaled $4.0 million, up 11% from the same year-ago quarter.
Gross profit was $5.1 million or 21.4% of total net revenues, compared to $4.3 million or 23.2% of total net revenues in the same year-ago quarter. The gross margin decrease is due to more competitive pricing in the marketplace, taking more deals from the competitors and pushing more business in the commercial/taxi arena versus retail only sales.
Net income totaled $260,000, as compared to net income of $251,000 in the same year-ago quarter.
First Half 2014 Financial Summary
Net revenues for the first half of 2014 totaled a record $44.5 million, up 32% from $33.7 million in the first half of 2013. Service and other revenue totaled $7.9 million, up 22% from the same year-ago period.
Gross profit was $10.4 million or 23.2% of total net revenues, compared to $7.8 million or 23.1% of total net revenues in the same year-ago period.
Net income totaled $455,000, as compared to net income of $52,000 in the same year-ago period.
Management Commentary
"In the second quarter of 2014, strong sales of handicap accessible vehicles across all of our East Coast dealerships resulted in a record topline with bottom line growth sequentially and year-over-year," said Hal Compton, CEO of HASCO Medical. "Subsequent to the quarter, we divested our durable medical equipment business, becoming a pure-play vehicular mobility provider. Based on our full focus on our leading mobility brands, strong tailwinds of a growing market and two new dealerships we're planning to open in the fall with the support of major brands like BraunAbility and VMI, we continue to expect record topline growth for the year."
About HASCO Medical, Inc
UGHS .062 HOUSTON, TX -- (Marketwired - August 05, 2014) - University General Health System, Inc. (OTCQB: UGHS) ("University General"), a diversified, multi-specialty, integrated, physician-centric general acute care regional health care delivery system, today announced the implementation of cost containment measures that are expected to result in permanent cost reductions and savings in excess of $13 million annually. The cost saving measures included salary and work force reductions, along with cutbacks in, and/or the elimination of, certain marketing and other initiatives that previously did not produce the desired outcomes.
UGH - Houston implemented an additional $2.7 million in permanent annualized cost reductions, in addition to previously reported expense reductions, some of which were seasonal in nature. Hospital Outpatient Departments accounted for $0.7 million in projected annual cost savings, UGHS Management Services expects to benefit from $3.1 million in annual expense reductions, Support Services lowered its costs by $2.2 million annually, and UGH - Dallas reduced expenses on an annual basis by $4.7 million. Some of these cost savings resulted from the elimination of nearly 100 jobs within the Company's operating network.
"Given the dynamic nature of the health care industry and our disappointing financial performance in 2013, we determined that drastic measures were required to remain competitive and restore profitability," stated Hassan Chahadeh, MD, Chairman and Chief Executive Officer of University General Health System, Inc. "While the implementation of these permanent cost-saving measures were often difficult, they were necessary and we are hopeful they will result in a positive impact upon our financial results during the balance of 2014 and in future years. We will also continue to focus on strategic relationships, the divestiture of non-core assets and the elimination of non-performing assets."
Ab
We're hoping that Arthur helps dump some rain inland as we are having a very dry summer.
UDHI does seem to have some potential so I'll be taking a look at it over the next couple of days.
I have some time on my hands since I've been "Arthured" out of fishing. All is not lost though, I am playing in a regional bridge tournament all next week.
The patent filings caught my attention. It's not cheap to do that, so they must think they have a good product here.
illegal,I owned shares of UDHI for a few years.I purchased shares for less than .01 and sold my shares for less than a penny.Now,the pps is moving up.The pps may continue to move up.But I will not repurchase shares unless earnings increase or the number of shares outstanding are decreased.
Joey, Salty, Genlou - look at UDHI - any thought on its recent history?
That one definitely looks promising and needs further research.
FUTU
Company Background
Future Healthcare of America (FHA) is engaged in the provision of healthcare services. It is engaged in homecare and staffing operations. FHA provides home care services, including senior care and pediatric nursing; physical, occupational, and speech therapy. FHA offices provide nurses, nurse aides and management services to hospitals, prisons, schools, corporations and other health care facilities. On June 8, 2012, Wizzard Software Corporation (WZE) formed Future Healthcare of America to spin-off the operations of Interim Health Care of Wyoming, Inc., (Interim) wherein WZE ownership of Interim was transferred to FHA. Future Healthcare of America is a parent company of Interim Healthcare of Wyoming, Inc. (Interim). Interim Healthcare of Wyoming, Inc. (Interim) is a home care and medical staffing company. Interim operates primarily in the home healthcare and healthcare staffing services in Wyoming and Montana.
http://www.interimhealthcare.com/wyoming
CHCR
Company Background
Advanzeon Solutions, Inc., formerly Comprehensive Care Corporation, provides managed care services in the behavioral health substance abuse, and psychotropic pharmacy management fields. The Company provides these services to commercial, Medicare, Medicaid and Children's Health Insurance Program (CHIP) health plans. It also provides prior and concurrent authorization for physician-prescribed psychotropic medications. Its managed care operations include administrative service agreements, fee-for-service agreements, and capitation contracts. It also provides prior and concurrent authorization for physician-prescribed psychotropic medications. The services provided through its provider network include outpatient programs (such as counseling or therapy), intermediate care programs (such as intensive outpatient programs and partial hospitalization services), and inpatient and crisis intervention services.
http://www.advanzeon.com
REPR
Company Background
REPRO-MED SYSTEMS, INC., (REPRO-MED) designs, manufactures, and markets medical devices primarily for the ambulatory infusion market and emergency medical applications. The Company's development and marketing focus are primarily concentrated on the FREEDOM60 Syringe Infusion System and accessories, and the RES-Q-VAC Emergency Medical Suction System. RES-Q-VAC is sold domestically and internationally by emergency medical device distributors. It markets the hospital RES-Q-VAC system through regional distributors specializing in the hospital respiratory care market. The FREEDOM60 Syringe Pump uses an engine to create a constant pressure drive system. FREEDOM60 uses tubing with slide clamp and luer-lock connector on the patient end. Its patented luer disc connector ensures that only the Company's FREEDOM60 tubing sets will function with the pump. The RES-Q-VAC Emergency Airway Suction System is a lightweight, portable, hand-operated suction device.
http://www.rmsmedicalproducts.com
With almost 80% of it's stock insider owned, maybe the time has come to take a close look at AOLS.
Let's see if this works and if you can post back
TY for the info. I think most of what I've looked at in health care stocks have been of the flipper variety.
I would be very careful with that one. Read StockBarber's posts on that board. I smell a possible scam in the making.
My background includes years a few years in intellectual property development - taking ideas from lab to market. That means patents, copyrights, trademarks, all sorts of IP. No way IMO that they can revive these patents. Also, their trademarks are meaningless in that simply putting TM next to something only means that you are asserting your claim to a particular mark. You would have to sue to enforce it = expensive. Not the same as registering it with the USPTO.
Provisional patents mean very little, since they are not examined and only hold a date if you file a full patent application later within 1 year of filing the provisional. With the implementation of the America Invents Act, they became worth even less. Also, anyone can file a coversheet application - don't need a lawyer for that. Patent lawyers are expensive - $400+/hour.
Also, the "patents" that they wish to revive have nothing to do with their current business plan. One of the hot topics right now is the buying and selling of patent portfolios. They are trying to play this angle.
I'll look into this some more. Might be worth a flip, but I see this as very risky.
Around 26% of OMCM is insider owned.
Company Background
OmniComm Systems, Inc. is a Web-based electronic data capture (EDC) and eClinical (eClinical) software and services that streamline the clinical research process. The Company's eClinical software and service offerings (eClinical Products or eClinical Solutions) include TrialMaster, TrialOne and eClinical Suite. The Company's eClinical Products are designed to allow clinical trial sponsors and investigative sites to collect, validate, transmit and analyze clinical study data. The Company's eClinical products are 21 CFR Part 11 compliant solutions and are designed to offer clinical trial sponsors the ability to conduct clinical trials under multiple platforms. The Company also provides business process consulting services that focus on integrating EDC and an array of eClinical Solutions and processes into the clinical trial process.
http://www.omnicomm.com
NSCT
Company Background
Cloud Medical Doctor Software Corporation , formerly National Scientific Corporation, incorporated on June 22, 1953, provide the Cloud-MD Office, a Cloud Based, 5010 and ICD-10 compliant, suite of medical software and services, designed by healthcare analysts and programmers for healthcare providers, that produces Actionable Information to help Independent Physician Practices, New Care Delivery Models (ACO). Cloud-MD Acquisition Services provides medical supply acquisition services that are integrated with Cloud-MD Office's Medical and Pharmaceutical Inventory Management software and offers a full range of medical, surgical, and laboratory supply products and equipment for medical offices and surgery centers. In March 2013, the Company acquired Doctors Network of America in Flowood, Mississippi.
http://www.cloud-mds.com
illegal, UGHS was profitable last quarter.
BCLI looks half way interesting.
Company Background
BrainStorm Cell Therapeutics Inc. is a biotechnology company developing autologous stem cell therapies for highly debilitating neurodegenerative disorders, such as Amyotrophic Lateral Sclerosis (ALS) (Lou Gehrig's disease), Multiple Sclerosis (MS) and Parkinson's disease (PD) and Spinal Cord Injury. These diseases have limited treatment options and as such represent unmet medical needs. NurOwn is BrainStorm's process for the propagation and differentiation of adult, autologous Mesenchymal Stem Cells (MSC) into NeuroTrophic Factor (NTF)-secreting cells, and the transplantation of these specialized cells at or near the affected tissue site. NurOwn offers the hope of repairing degenerated tissues and curing the underlying pathology, rather than treating its symptoms. BrainStorm is conducting clinical trials with NurOwn in ALS patients. In February 2011, the United States Food and Drug Administration (FDA) granted Orphan Drug designation to NurOwn for the treatment of ALS.
http://www.brainstorm-cell.com/
Followers
|
3
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
130
|
Created
|
12/16/13
|
Type
|
Premium
|
Moderator illegal_alias | |||
Assistants |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |